Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer

Abstract

Evidence is evolving for the use of PET-CT in anal cancer. Because of a high negative predictive value, our series shows that PET-CT can be used in the assessment of treatment response to exclude residual/recurrent disease.